Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALLERFED vs ADVIL ALLERGY SINUS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ALLERFED is a combination of an antihistamine (fexofenadine) and a decongestant (pseudoephedrine). Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine effects, reducing allergy symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor activation, causing vasoconstriction of nasal mucosa.
Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction of nasal mucosa and sinus vessels. Chlorpheniramine is an alkylamine antihistamine that competitively antagonizes histamine H1 receptors, reducing allergic symptoms. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, decreasing prostaglandin synthesis and reducing pain, fever, and inflammation.
Seasonal allergic rhinitis,Perennial allergic rhinitis,Nasal congestion associated with allergies
Temporary relief of nasal congestion, sinus pressure, sneezing, runny nose, itchy/watery eyes, and headache due to colds or allergies,Fever reduction,Minor aches and pains
1 tablet (pseudoephedrine 60 mg / triprolidine 2.5 mg) orally every 4-6 hours; not to exceed 4 doses per 24 hours.
1-2 tablets (each tablet contains ibuprofen 200 mg and pseudoephedrine HCl 30 mg) orally every 4-6 hours as needed; maximum 6 tablets per day.
Terminal elimination half-life 20-24 hours; clinically significant for once-daily dosing in seasonal allergic rhinitis.
2–4 hours (pseudoephedrine: 5–8 hours); clinical context: requires q4-6h dosing for pain/fever, q6-8h for congestion
Fexofenadine is minimally metabolized (<5%) in the liver; primarily excreted unchanged in feces (80%) and urine (11%). Pseudoephedrine is partially metabolized in the liver by N-demethylation and excreted mostly unchanged in urine.
Ibuprofen: Primarily hepatic via CYP2C9; Pseudoephedrine: Hepatic via N-demethylation and oxidative metabolism; Chlorpheniramine: Hepatic via CYP2D6 and CYP3A4.
Primarily renal (approximately 60-70% as unchanged drug and metabolites); minor biliary (10-15%); fecal (5-10%).
Renal (90% as conjugates and metabolites; <10% unchanged); biliary/fecal (<5%)
80-85% bound to albumin and alpha-1-acid glycoprotein.
Ibuprofen: >99% (albumin); pseudoephedrine: <20% (albumin)
Vd 5-7 L/kg, indicating extensive tissue distribution beyond plasma volume.
Ibuprofen: 0.1–0.2 L/kg; pseudoephedrine: 2.5–3.5 L/kg (extensive tissue distribution)
Oral: 40-50% due to first-pass metabolism; intranasal: 70-80%.
Ibuprofen: 80–100% oral; pseudoephedrine: >90% oral
Cr Cl 30-50 m L/min: administer every 6-8 hours. Cr Cl 10-29 m L/min: administer every 8-12 hours. Cr Cl <10 m L/min: not recommended.
If GFR <30 m L/min: avoid use of ibuprofen component; pseudoephedrine dose interval may need to be increased (every 8-12 hours) due to reduced clearance.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50% or extend interval. Child-Pugh Class C: avoid use.
Child-Pugh Class A: no adjustment; Class B: use with caution, maximum ibuprofen dose 1200 mg/day; Class C: contraindicated due to risk of hepatotoxicity and renal impairment.
Children 6-12 years: 1/2 tablet (pseudoephedrine 30 mg / triprolidine 1.25 mg) orally every 4-6 hours; max 2 doses per 24 hours. Children <6 years: not recommended.
Not recommended for children under 12 years of age; for children ≥12 years: same as adult dose (200 mg ibuprofen/30 mg pseudoephedrine) every 4-6 hours, maximum 6 tablets per day.
Initiate at half the adult dose; monitor for anticholinergic effects, dizziness, and hypertension; maximum 2 doses per 24 hours.
Initiate at lowest effective dose (1 tablet every 6-8 hours); monitor renal function and blood pressure due to increased risk of GI bleeding, cardiovascular events, and pseudoephedrine-induced hypertension.
None.
No FDA black box warning exists for this combination product. However, NSAIDs like ibuprofen carry a black box warning for increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal, especially with prolonged use or in patients with cardiovascular risk factors.
Severe hypertension,Coronary artery disease,Ischemic heart disease,Increased intraocular pressure,Diabetes,Thyroid disease,Prostatic hypertrophy,Renal impairment,Use with caution in elderly,Avoid with MAOIs or within 14 days of stopping
Cardiovascular risk: NSAIDs increase risk of serious cardiovascular events. Gastrointestinal risk: NSAIDs can cause bleeding, ulceration, and perforation. Hypertension: Pseudoephedrine may elevate blood pressure. Avoid use with MAOIs or within 14 days of stopping. Caution in hyperthyroidism, diabetes, glaucoma, prostatic hypertrophy, and renal impairment.
Hypersensitivity to any component,Severe hypertension,Severe coronary artery disease,Use with or within 14 days of MAOIs,Narrow-angle glaucoma,Urinary retention,Severe renal impairment (Cr Cl <30 m L/min)
Hypersensitivity to any component; Concurrent MAOI therapy; Severe hypertension or coronary artery disease; Active peptic ulcer disease; History of aspirin/NSAID-induced asthma; Pregnancy (especially third trimester); Children under 12 years (per product labeling).
Avoid high-tyramine foods (e.g., aged cheeses, cured meats, fermented foods) if taking MAOIs concurrently. Grapefruit juice may increase absorption of triprolidine. Caffeine may enhance stimulant effects of pseudoephedrine.
Avoid alcohol due to increased risk of GI bleeding and liver toxicity. No known food interactions with chlorpheniramine or pseudoephedrine. Taking with food may reduce gastric irritation from ibuprofen.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies suggest possible increased risk of minor malformations. Second/third trimester: Use associated with reduced uterine blood flow and fetal tachycardia; avoid near term due to risk of prolonged QT interval in neonate.
First trimester: NSAIDs are associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Third trimester: Risk of premature closure of ductus arteriosus, oligohydramnios, and necrotizing enterocolitis. Avoid use after 30 weeks gestation.
Excreted in breast milk with M/P ratio of approximately 0.5. American Academy of Pediatrics considers compatible with breastfeeding; however, use with caution due to potential for irritability and drowsiness in infant.
Ibuprofen and pseudoephedrine are excreted into breast milk. Ibuprofen has low milk/plasma ratio (0.01-0.07) and is generally considered compatible. Pseudoephedrine may reduce milk production and cause irritability in infants. Use with caution, especially in preterm infants.
Increased plasma volume and renal clearance in pregnancy may reduce drug concentrations; however, specific dose adjustment is not routinely recommended due to limited data. Use lowest effective dose for shortest duration.
No specific dose adjustments recommended for pregnancy; however, use the lowest effective dose for the shortest duration. Avoid in third trimester. Pseudoephedrine dose remains standard; caution in hypertensive disorders.
Allerfed combines pseudoephedrine and triprolidine. Use with caution in hypertension, cardiovascular disease, and glaucoma. Avoid in patients with severe hypertension or coronary artery disease. Limit duration to 5-7 days to avoid rebound congestion. Anticholinergic effects may cause urinary retention in BPH.
Advil Allergy Sinus contains ibuprofen (NSAID), chlorpheniramine (first-generation antihistamine), and pseudoephedrine (decongestant). Avoid in patients with aspirin/NSAID allergy, severe hypertension, coronary artery disease, or MAOI use. Caution in elderly due to anticholinergic effects. Pseudoephedrine may cause insomnia and anxiety; avoid evening dosing.
Take with food or milk to reduce stomach upset.,Do not exceed recommended dose; avoid taking more than every 4-6 hours.,Avoid alcohol while taking this medication.,If symptoms persist for more than 7 days, consult your doctor.,May cause drowsiness; avoid driving or operating heavy machinery until you know how you react.
Do not take if allergic to aspirin or NSAIDs.,Avoid alcohol to reduce risk of stomach bleeding.,Do not use with other products containing NSAIDs or decongestants.,May cause drowsiness; avoid driving or operating machinery.,Do not take for more than 10 days for pain or 3 days for fever.,Consult a doctor if you have high blood pressure, heart disease, glaucoma, or an enlarged prostate.,Pseudoephedrine may cause difficulty sleeping; take last dose at least 4-6 hours before bedtime.,Take with food or milk to minimize stomach upset.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALLERFED vs ADVIL ALLERGY SINUS, answered by our medical review team.
ALLERFED is a Decongestant that works by ALLERFED is a combination of an antihistamine (fexofenadine) and a decongestant (pseudoephedrine). Fexofenadine is a selective peripheral H1-receptor antagonist that blocks histamine effects, reducing allergy symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor activation, causing vasoconstriction of nasal mucosa.. ADVIL ALLERGY SINUS is a NSAID/Decongestant/Antihistamine Combination that works by Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction of nasal mucosa and sinus vessels. Chlorpheniramine is an alkylamine antihistamine that competitively antagonizes histamine H1 receptors, reducing allergic symptoms. Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, decreasing prostaglandin synthesis and reducing pain, fever, and inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALLERFED and ADVIL ALLERGY SINUS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALLERFED is: 1 tablet (pseudoephedrine 60 mg / triprolidine 2.5 mg) orally every 4-6 hours; not to exceed 4 doses per 24 hours.. The standard adult dose of ADVIL ALLERGY SINUS is: 1-2 tablets (each tablet contains ibuprofen 200 mg and pseudoephedrine HCl 30 mg) orally every 4-6 hours as needed; maximum 6 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALLERFED and ADVIL ALLERGY SINUS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALLERFED is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data; animal studies suggest possible increased risk of minor malformations. Second/third trimester: Use associated with re. ADVIL ALLERGY SINUS is classified as Category C. First trimester: NSAIDs are associated with increased risk of miscarriage and congenital malformations (cardiac defects, gastroschisis). Third trimester: Risk of premature closure . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.